Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetologia ; 54(11): 2820-31, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21822931

ABSTRACT

AIMS/HYPOTHESIS: The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2. Variants in GCG may associate with type 2 diabetes, obesity and/or related metabolic traits. METHODS: GCG was re-sequenced as a candidate gene in 865 European individuals. Twenty-nine variants were identified. Four variants that were considered to have a likelihood for altered functionality: rs4664447, rs7581952, Ile158Val and Trp169Ter, were genotyped in 17,584 Danes. RESULTS: When examined in 5,760 treatment-naive individuals, homozygous carriers of the low frequency (minor allele frequency 2.3%) G allele of rs4664447, predicted to disrupt an essential splice enhancer binding site, had lower levels of fasting plasma glucose (mean ± SD, 4.8 ± 1.2 vs 5.5 ± 0.8 mmol/l, p = 0.004); fasting serum insulin (22 ± 14 vs 42 ± 27 pmol/l, p = 0.04); glucose-stimulated serum insulin (159 ± 83 vs 290 ± 183 pmol/l, p = 0.01) and adult height (165 ± 10 vs 172 ± 9 cm, p = 0.0009) compared with A allele carriers. During oral glucose tolerance and hyperglycaemic arginine stimulation tests, the plasma AUC for GLP-1 (730 ± 69 vs 1,334 ± 288 pmol/l × min, p = 0.0002) and basal and stimulated levels of serum insulin and plasma glucagon were ∼50% decreased (p < 0.001) among three homozygous carriers compared with nine matched wild-type carriers. rs7581952, Ile158Val and Trp169Ter (where 'Ter' indicates 'termination') variants of GCG did not significantly associate or co-segregate with the metabolic traits examined. CONCLUSIONS/INTERPRETATION: Re-sequencing of GCG revealed a low frequency intronic variant, rs4664447, and follow-up physiological studies suggest that this variant in homozygous form may cause decreased fasting and stimulated levels of insulin, glucagon and GLP-1. Overall, our findings suggest that variation in GCG has no major impact on carbohydrate metabolism in the study populations examined.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/genetics , Glucagon-Like Peptide 1/blood , Glucagon/blood , Glucagon/genetics , Insulin/blood , Polymorphism, Single Nucleotide , Adolescent , Adult , Age of Onset , Aged , Case-Control Studies , Child , Child, Preschool , Czechoslovakia , Denmark , Diabetes Mellitus, Type 2/complications , Europe , Female , Genetic Association Studies , Glucagon-Like Peptide 1/genetics , Homozygote , Humans , Infant , Insulin/metabolism , Insulin Resistance , Insulin Secretion , Male , Middle Aged , Obesity/blood , Obesity/complications , Obesity/genetics
2.
Gut ; 53(8): 1145-50, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15247183

ABSTRACT

BACKGROUND: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine. AIMS: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated. METHODS: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 microg GLP-2, 25 microg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above. RESULTS: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment. CONCLUSIONS: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.


Subject(s)
Colonic Neoplasms/pathology , Peptides/adverse effects , Adenoma/pathology , Adenoma/physiopathology , Animals , Body Weight , Colonic Neoplasms/chemically induced , Colonic Polyps/chemically induced , Colonic Polyps/pathology , Female , Glucagon-Like Peptide 2 , Glucagon-Like Peptides , Intestinal Mucosa/pathology , Intestine, Small/pathology , Mice , Mice, Inbred C57BL , Organ Size
3.
Regul Pept ; 115(2): 91-9, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12972324

ABSTRACT

Peptides of the trefoil factor family (TFF1, TFF2 and TFF3) are co-secreted with mucus in most organ systems and are believed to interact with mucins to produce high-viscosity, stable gel complexes. We have previously demonstrated that cells in the GI tract possess binding sites to TFF2 and that injected TFF2 ends up in the mucus layer. In the present study, tissue binding and metabolism of parenterally administered human TFF1 and TFF3 in rats were described and compared to the immunohistochemical localization of the TFF peptides. 125I-TFF1 monomer and 125I-TFF3 mono- and dimer were given intravenously to female Wistar rats. The tissue distribution was assessed by gamma counting of organ samples and by autoradiography of histological sections. The degradation of 125I-TFF3 was studied by means of trichloracetic acid (TCA) precipitation and the saturability of the binding by administration of excess unlabelled peptide. The TFF peptides were localized in histologic sections from the GI tract by immunohistochemistry. Injected TFF3 dimer (12%) was taken up by the GI tract. At autoradiography, grains were localized to the same cells that were immunoreactive to TFF2. The binding could be displaced by excess TFF3. Similar binding was observed for the TFF1 and TFF3 monomers apart from binding in the stomach, where the uptake was only 15% in comparison to the dimer. There was no specific binding outside the GI tract and no binding to TFF1 or TFF3 immunoreactive cells. In conclusion, the TFF2-binding cells in the gastrointestinal tract seem to have basolateral, receptor-like activity to all three TFF peptides. The mucous neck cells of the stomach predominantly take up TFFs with two trefoil domains, indicating a different receptor-like activity in the stomach compared to the rest of the GI tract.


Subject(s)
Digestive System/metabolism , Growth Inhibitors/metabolism , Mucins/metabolism , Muscle Proteins/metabolism , Neuropeptides , Peptide Fragments/pharmacology , Peptides/metabolism , Proteins/metabolism , Animals , Cells, Cultured , Estrogens/metabolism , Female , Growth Inhibitors/administration & dosage , Humans , Immunoenzyme Techniques , Injections, Intravenous , Iodine Radioisotopes , Mucins/administration & dosage , Muscle Proteins/administration & dosage , Proteins/administration & dosage , Rats , Rats, Wistar , Tissue Distribution , Trefoil Factor-1 , Trefoil Factor-2 , Trefoil Factor-3 , Tumor Suppressor Proteins
4.
Dig Dis Sci ; 46(2): 379-88, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11281189

ABSTRACT

Glucagon-like peptide 2 (GLP-2), produced by enteroendocrine L-cells, regulates intestinal growth. This study investigates circulating and intestinal GLP-2 levels in conditions with altered L-cell exposure to nutrients. Rats were allocated to the following experimental groups: ileal-jejunal transposition, resection of the proximal or distal half of the small intestine, and appropriate sham-operated controls. After two weeks, ileal-jejunal transposition led to pronounced growth of the transposed segment and also of the remaining intestinal segments. Plasma GLP-2 levels increased twofold, whereas GLP-2 levels in the intestinal segments were unchanged. In resected rats with reduced intestinal capacity, adaptive small bowel growth was more pronounced following proximal resection than distal small bowel resection. Circulating GLP-2 levels increased threefold in proximally resected animals, and twofold in the distally resected group. Tissue GLP-2 levels were unchanged in resected rats. The data indicate that transposition of a distal part of the small intestine, and thereby exposure of L cells to a more nutrient-rich chyme, leads to intestinal growth. The adaptive intestinal growth is associated with increased plasma levels of GLP-2, and GLP-2 seems to act in an endocrine as well as a paracrine manner.


Subject(s)
Adaptation, Physiological/physiology , Ileum , Jejunum , Models, Animal , Peptides/blood , Peptides/physiology , Animals , Body Weight , Energy Intake , Enteroendocrine Cells/physiology , Female , Glucagon-Like Peptide 2 , Glucagon-Like Peptides , Ileum/chemistry , Ileum/growth & development , Ileum/surgery , Ileum/transplantation , Jejunum/chemistry , Jejunum/growth & development , Jejunum/surgery , Jejunum/transplantation , Peptides/analysis , Rats , Rats, Wistar
5.
Endocrinology ; 141(11): 4013-20, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11089531

ABSTRACT

Glucagon-like peptide-2 (GLP-2) induces intestinal growth in mice; but in normal rats, it seems less potent, possibly because of degradation of GLP-2 by the enzyme dipeptidyl peptidase IV (DPP-IV). The purpose of this study was to investigate the survival and effect of GLP-2 in rats and mice after s.c. injection of GLP-2 with or without the specific DPP-IV inhibitor, valine-pyrrolidide (VP). Rats were injected s.c. with 40 microg GLP-2 or 40 microg GLP-2+15 mg VP. Plasma was collected at different time points and analyzed, by RIA, for intact GLP-2. Rats were treated for 14 days with: saline; 15 mg VP; 40 microg GLP-2, 40 microg GLP-2+15 mg VP; 40 microg GLP-2 (3-33). Mice were treated for 10 days with: saline; 5 microg GLP-2; 5 microg GLP-2+1.5 mg VP; 25 microg GLP-2; 25 microg GLP-2 (3-33). In both cases, body weight, intestinal weight, length, and morphometric data were measured. After s.c. injection, the plasma concentration of GLP-2 reached a maximum after 15 min, and elevated concentrations persisted for 4-8 h. With VP, the concentration of intact GLP-2 was about 2-fold higher for at least the initial 60 min. Rats treated with GLP-2+VP had increased (P < 0.01) small-bowel weight (4.68 +/- 0.11%, relative to body weight), compared with the two control groups, [3.01 +/- 0.06% (VP) and 2.94 +/- 0.07% (NaCl)] and GLP-2 alone (3.52 +/- 0.10%). In mice, the growth effect of 5 microg GLP-2+VP was comparable with that of 25 microg GLP-2. GLP-2 (3-33) had no effect in rats, but it had a weak effect on intestinal growth in mice. The extensive GLP-2 degradation in rats can be reduced by VP, and DPP-IV inhibition markedly enhances the intestinotrophic effect of GLP-2 in both rats and mice. We propose that DPP-IV inhibition may be considered to enhance the efficacy of GLP-2 as a therapeutic agent.


Subject(s)
Dipeptidyl Peptidase 4/metabolism , Enzyme Inhibitors/pharmacology , Intestines/drug effects , Intestines/growth & development , Peptides/pharmacology , Animals , Body Weight , Female , Glucagon-Like Peptide 2 , Glucagon-Like Peptides , Humans , Mice , Mice, Inbred C57BL , Organ Size , Peptides/metabolism , Pyrroles/pharmacology , Rats , Rats, Wistar , Recombinant Proteins/pharmacology , Valine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...